Josh Bilenker on Blogger

About Josh Bilenker

Based in Stamford, Connecticut, Josh Bilenker, MD, serves as CEO of Loxo Oncology at Lilly, overseeing its oncology research and development activities. Responsible for everything from target selection to initial US approval, Dr. Bilenker, has been charged with revamping oncology R&D at Lilly.

Dr. Bilenker founded Loxo Oncology in 2013, and was successful in creating a robust drug development pipeline that included FDA approved therapies Vitrakvi and Retevmo, as well as LOXO-305. He earned international recognition for his innovative approach to clinical-regulatory strategy, which put the precision medicine at the center of all decision making.. These approaches led to therapeutic advances in rare populations and pediatric cancer. The Loxo Oncology pipeline also employed real-time analysis of emerging resistance mechanisms so as to launch second-generation programs more quickly . Since early 2019, Loxo Oncology has operated as a wholly owned subsidiary of Eli Lilly and Company.

Dr. Bilenker’s background includes 13 years of various roles with the life sciences venture capital firm Aisling Capital. As a partner at this company, Josh Bilenker, MD, was responsible for screening and due diligence related to investments in medical devices, diagnostics, and therapeutics.